Q-omics provides the consensus-scored ANKS4B profile across patient tissues and cancer cell-line models. ANKS4B expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ANKS4B is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, ANKS4B RNA expression shows 13,052 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KIRC, KICH, and ESCA as cancer lineages where ANKS4B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKS4B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKS4B survival associations across molecular data types. ANKS4B RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKS4B RNA expression–survival associations across cancer types. High ANKS4B expression shows unfavorable associations in KICH and CESC, but favorable associations in KIRC, READ, KIRP and ACC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ANKS4B RNA expression.
This table summarizes ANKS4B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 3. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ANKS4B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKS4B shows lower tumor expression in KICH, KIRP, COAD and CHOL and higher tumor expression in STAD and LUAD. The KICH box plot shows higher ANKS4B RNA expression in normal versus tumor tissue (log2 FC = −2.844, t-test p < 0.001).
This table shows molecular features associated with ANKS4B in patient tissues and cancer cell lines. In patient samples, ANKS4B shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKS4B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
